LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Prothena Corp PLC

Geschlossen

BrancheGesundheitswesen

5.39 6.52

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.01

Max

5.43

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.2M

-60M

Verkäufe

705K

2.8M

EPS

-1.12

Gewinnspanne

-2,128.536

Angestellte

163

EBITDA

-682K

-65M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+380.04% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-495M

251M

Vorheriger Eröffnungskurs

-1.13

Vorheriger Schlusskurs

5.39

Nachrichtenstimmung

By Acuity

50%

50%

167 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Prothena Corp PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Juni 2025, 20:45 UTC

Ergebnisse

Broadcom 2Q Sales Climb on Booming AI Demand

5. Juni 2025, 23:45 UTC

Market Talk

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5. Juni 2025, 23:44 UTC

Market Talk

Gold Edges Higher on Weak U.S. Data -- Market Talk

5. Juni 2025, 23:30 UTC

Market Talk

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5. Juni 2025, 21:32 UTC

Ergebnisse

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5. Juni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

5. Juni 2025, 20:45 UTC

Ergebnisse

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5. Juni 2025, 20:24 UTC

Ergebnisse

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5. Juni 2025, 20:15 UTC

Ergebnisse

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5. Juni 2025, 20:15 UTC

Ergebnisse

Broadcom 2Q Rev $15B >AVGO

5. Juni 2025, 20:15 UTC

Ergebnisse

Broadcom 2Q Net $4.97B >AVGO

5. Juni 2025, 20:15 UTC

Ergebnisse

Broadcom 2Q Adj EPS $1.58 >AVGO

5. Juni 2025, 20:15 UTC

Ergebnisse

Broadcom 2Q EPS $1.03 >AVGO

5. Juni 2025, 20:15 UTC

Ergebnisse

Broadcom Sees 3Q Rev $15.8B >AVGO

5. Juni 2025, 20:11 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5. Juni 2025, 20:11 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5. Juni 2025, 20:11 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5. Juni 2025, 19:22 UTC

Market Talk

Oil Futures Resume Upward Moves -- Market Talk

5. Juni 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5. Juni 2025, 18:32 UTC

Market Talk

Gold Slips After Trump-Xi Call -- Market Talk

5. Juni 2025, 18:26 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5. Juni 2025, 18:06 UTC

Market Talk

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5. Juni 2025, 16:30 UTC

Akquisitionen, Fusionen, Übernahmen

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5. Juni 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

5. Juni 2025, 16:18 UTC

Market Talk

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5. Juni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. Juni 2025, 16:12 UTC

Market Talk

Global Energy Roundup: Market Talk

5. Juni 2025, 16:12 UTC

Market Talk

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5. Juni 2025, 16:03 UTC

Market Talk

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5. Juni 2025, 15:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Prothena Corp PLC Prognose

Kursziel

By TipRanks

380.04% Vorteil

12-Monats-Prognose

Durchschnitt 24.29 USD  380.04%

Hoch 81 USD

Tief 4 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Prothena Corp PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

4

Buy

4

Halten

1

Sell

Technischer Score

By Trading Central

N/A / 7.35Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

167 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.